Health economics connects NHS decision-making to pharmaceutical and medtech innovation. Understanding it and using it well is one of the most effective routes to getting the latest treatments to the right patients.
.png)
Every funding decision the NHS makes is also, simultaneously, a divestment decision. Choosing to green-light one treatment, technology, or care pathway means not funding something else. In a system serving millions of people on a fixed and finite budget, facing rising demand from an ageing population with increasingly complex needs, the question of how to distribute that budget is highly consequential.
Health economics is the discipline that makes those decisions structured, defensible, and, at its best, fair. It is also, for many people working in or alongside the NHS, one of the most misunderstood. NHS commissioners can encounter it as a constraint, pharmaceutical and medtech companies as a barrier and patients, if they encounter it at all, tend to encounter it indirectly, as the reason a treatment they need is or is not available to them.
None of these framings is entirely wrong, but none captures the full picture. Health economics, applied well, is a tool for maximising patient benefit within a system that will always have more demand than supply. And the NHS 10-year health plan, with its shift towards prevention, earlier detection, and population-level outcomes, makes that case more pressing.
Economic evaluation in healthcare compares the costs and consequences of different interventions. It is not primarily about finding the cheapest option; instead, it aims to find the option that delivers the most health benefit relative to its cost and, crucially, to what else the money could have been spent on, the opportunity cost. This can be understood as the health benefits foregone when resources go to one intervention rather than another.
The main evaluation frameworks each answer a slightly different question. Cost-effectiveness analysis (CEA) measures outcomes in natural units — cases detected, hospitalisations avoided, life years gained — and asks what it costs to achieve one unit of that outcome. Cost-utility analysis (CUA) goes further, using a composite measure, the quality-adjusted life year, or QALY, that combines both the length and the quality of the life gained. Cost-benefit analysis (CBA) converts health outcomes into monetary values, allowing comparison across sectors and programmes but involving judgements that are contested in practice. Cost-consequence analysis (CCA) presents costs and multiple outcomes side by side without aggregating them, useful where decision-makers want to weigh different dimensions of value.
The QALY is the currency of NHS decision-making. It quantifies health benefit as the combination of how many additional years of life an intervention provides and the quality of those years, where one year in full health equals one QALY. NICE uses a cost-per-QALY threshold to guide its recommendations: broadly, interventions costing less than £25,000 to £35,000 per QALY gained are considered cost-effective under standard guidance, though the thresholds vary by pathway and context. Those figures are themselves newly updated: from April 2026, following the US-UK trade agreement reached in December 2025, the standard threshold range will rise from £20,000–£30,000 to £25,000–£35,000, the first increase since NICE’s founding in 1999. The ABPI has noted that even the new upper figure remains around 47% lower in real terms than the original threshold adjusted for inflation, which suggests the debate about whether the bar is set at the right level is far from over. This single figure has more influence over which treatments reach NHS patients than almost any other number in UK healthcare policy, which makes understanding what drives it, and where it has known limitations, essential knowledge for life science companies seeking NHS adoption of a new therapy or technology.
QALYs are known to undervalue certain types of benefit. Treatments for rare diseases, interventions that primarily benefit working-age adults, and end-of-life therapies can all look less cost-effective under standard QALY frameworks than their value to patients and families would suggest. The model also struggles to capture wider societal value: the benefit to an unpaid carer when a patient retains independence for longer, the economic gain when someone returns to work after effective treatment, or the downstream savings when a medicine reduces hospital admissions that sit in a different budget. NICE has developed modified appraisal pathways to address some of these gaps such as the Highly Specialised Technologies pathway for ultra-rare conditions, but the limitations of the QALY framework remain an area of live and contested debate. Anti-obesity medicines and the first disease-modifying Alzheimer’s drugs to reach the UK are recent examples where those limitations have been tested in practice, as explored later in this article. Companies developing products in these affected areas need to understand which pathway applies and why, because the answer will shape the evidence strategy.
The NHS 10-year health plan does not change the fundamentals of health economics. But it does shift the priorities against which economic arguments are evaluated and that has practical consequences for how commissioners think, and how life science companies should frame their value propositions.
The plan's central ambition is a shift from reactive, hospital-centred care to proactive, community-based prevention. Economically, this changes the time horizon over which value is measured. A falls prevention programme, an early cardiovascular screening initiative, or a pharmacist-led medication review may not generate immediate cost savings, but modelled over a population, over time, accounting for downstream avoidance of emergency admissions, acute care episodes, and long-term complications, the return on investment can be substantial. Public Health England's suite of ROI tools, covering cardiovascular disease, falls prevention, mental health, and other priority areas, exists precisely because that modelling work is needed so that local commissioners can access the information and apply it to their own populations.
Integrated Care Boards have been in place since 2022, but their remit is being sharpened considerably. The Model ICB Blueprint, published in May 2025, set out how ICBs are expected to evolve into focused strategic commissioning bodies responsible for a population's health across the full pathway: primary, community, secondary, and social care. That broader accountability has direct economic implications. The economic case for a new intervention now needs to be made at system level, not just within a single care setting. A product that generates savings in secondary care by reducing admissions, but whose costs sit in primary care, requires a system-level economic model to make its value visible. Commissioners working across both settings need the evidence framed accordingly. This is one of the areas where the transition to integrated care is still catching up with its own ambitions.
The plan is also explicit about productivity. NHS workforce capacity is an economic variable, not just an operational one. The economic case for AI-enabled tools, digital care pathways, and technology that reduces administrative burden now routinely includes the value of clinical time released. For medtech companies in particular, this creates a stronger framing for technologies that improve efficiency at the point of care: their value is not only clinical but also systemic, and a health economics argument that captures both is compelling.
hurdle to clear at the end of the development process. It is a discipline to engage with from the start, and the companies that do this consistently are better positioned at every subsequent stage.
The evidence package supporting a NICE submission has become more demanding over time, and real-world applicability has become increasingly necessary. Trial populations that do not reflect the diversity of NHS patients, clinical endpoints that do not map cleanly to the outcomes commissioners care about, and economic models that rely on assumptions that break down under scrutiny are weaknesses that could trip up market access for valuable technologies.
Real-world evidence is increasingly central to this. NICE's methods and the NHS commissioning frameworks are moving towards a greater emphasis on evidence generated in routine clinical practice. For companies with products already in use in comparable international health systems, systematically building that evidence base and presenting it in a format that maps to NHS commissioning priorities, ICB population data, and the specific care pathways relevant to their disease area, significantly strengthens the economic argument. The question 'what does this cost the NHS per QALY gained, in this population, in this setting?' should have a clear and well-supported answer before the commissioning conversation begins.
The NHS-Industry Partnership framework, governed by ABPI guidelines for collaborative and joint working, is an underused mechanism for generating exactly this kind of evidence. Structured programmes that bring a company's clinical and commercial resources together with NHS organisations' data, patient populations, and clinical expertise can generate real-world evidence, support pathway development, and demonstrate value in a live NHS context. For companies developing treatments in disease areas where diagnosis rates are low, patient identification is poor, or treatment access is inequitable, this kind of structured engagement is often the most direct route to patients who need it.
For companies that deploy outsourced field teams within the NHS, including Key Account Managers and market access specialists working to support clinical adoption of new treatments and technologies, health economics is a core competency. The ability to present a coherent economic argument to an ICB medicines optimisation committee, to translate a NICE recommendation into a local commissioning conversation, or to frame a product's value in terms that resonate with a budget-holder who is simultaneously managing 12 other priorities: these are the skills that determine whether a clinically important treatment reaches the patients it could help. Equipping those teams well with the NHS insight, the economic literacy, and the relationship infrastructure to operate effectively is one of the most direct investments a pharmaceutical or medtech company can make in patient access.
No discussion of health economics in the NHS is complete without addressing its known limitations.
Cost-effectiveness analyses based on population averages can mask significant variation. A treatment that looks cost-effective at the aggregate level may deliver considerably less benefit, or carry greater risk, in specific demographic groups. The NHS's own cardiovascular screening tools and the skin cancer diagnostics discussed in AI trials are both examples of technologies that perform well on average but have known performance gaps across ethnicity and skin type. The 10-year plan's equity agenda requires economic evaluation to better capture this variation, not just report an average.
The return-on-investment framing which Public Health England's tools use extensively has its own limitations. Long-term societal benefits are modelled from assumptions about what would have happened in the absence of an intervention. Those assumptions are reasonable, but they are not certainties. Commissioners who understand the uncertainty bands around an ROI estimate are better positioned to use it than those who treat the headline figure as a guarantee.
There is also a tension that health economics cannot fully resolve: the difference between what is cost-effective for the population and what is right for the individual patient in front of a clinician. The NICE framework is explicit that a recommendation should be made if an intervention is cost-effective, regardless of the total budget impact of implementing it across the population; the resource impact analysis is a separate exercise. But the real-world experience of commissioners working with constrained budgets and competing priorities is more complicated than the framework suggests. Understanding that tension is part of what it means to engage seriously with health economics.
Health economics exists to maximise benefit for the population within finite resources. Its purpose is patient benefit, not cost containment for its own sake.
Patients are, ultimately, the reason this discipline matters. Every QALY calculation, every cost-effectiveness model, every commissioning decision informed by economic evidence represents a judgement about whose health gets improved and by how much. Getting those judgements right, equitably, across different populations and disease areas, is deeply important for the NHS. The tools of health are among the most reliable means of doing so, which makes it all the more important to understand where they fall short.
Two recent and high-profile examples illustrate, in concrete terms, where the model produces outcomes that are difficult to defend on patient grounds.
In June 2025, NICE rejected two drugs representing the first disease-modifying treatments for Alzheimer’s disease in a generation. Both had been licensed by the MHRA as safe. The rejection was based on the assessment that their benefit, a 27–33% slowing of cognitive decline over 18 months, was “statistically significant but not clinically meaningful” when translated into QALY terms. Industry and patient groups challenged both the methodology and the conclusion. Their central argument: the standard QALY model failed to account for the societal value of the unpaid carer. Keeping a patient independent for six months longer, able to manage daily tasks, socialise, and retain a degree of autonomy, significantly reduces the burden on the family member or partner providing care, many of whom reduce or leave employment to do so. That benefit does not appear in the QALY calculation in any meaningful way.
A second strand of criticism concerned the cost side of the equation. NICE included the substantial infrastructure costs of establishing infusion clinics and MRI monitoring protocols, necessary for safe administration, in its assessment of these drugs’ cost-effectiveness. Industry argued these are system-level investments in dementia diagnostic capacity that should not be charged entirely against the first two products to enter the market; without them, the drugs would have come considerably closer to the cost-effectiveness threshold.
Following a successful manufacturer appeal, NICE announced in March 2026 that it must reconsider both decisions. The re-evaluation will use the new £25,000–£35,000 threshold that comes into force in April 2026, and NICE has confirmed that caregiver quality of life will be a central pillar of the reassessment, a direct acknowledgement that the original model was too narrow. The outcome of that process will be closely watched: if these drugs are approved on re-evaluation, it will signal a meaningful shift towards a model that takes societal value more seriously.
GLP-1 receptor agonists present a different kind of problem. For this class of anti-obesity medicines, the economic case, through standard QALY modelling, is, in many respects, compelling: reducing severe obesity yields significant downstream savings across diabetes, cardiovascular disease, and musculoskeletal conditions, and the quality-of-life gains are substantial. The challenge NICE faces is not that the model produces the wrong answer on cost-effectiveness grounds, but that the NHS does not currently have the workforce or the commissioning infrastructure to deliver these medicines at the scale the model implies it should. There are not enough GPs or specialist pharmacists, and the funding pathways across primary and secondary care are not designed for a therapy of this population-level demand.
This highlights a limitation the QALY framework was not designed to address: system readiness. A therapy can be cost-effective in the technical sense and simultaneously undeliverable at the recommended scale within the current NHS. For companies in this position, the economic argument alone is not enough — the access case needs to engage with capacity and commissioning infrastructure as explicitly as it engages with clinical evidence. It is also a reminder that health economics operates within a system, not above it, and the system has constraints that the model cannot simply override.
The gap between a clinical innovation that works and one that reaches patients at scale is frequently an economic gap. Not in the sense of cost alone, but in the sense of evidence quality, commissioning literacy, and the ability to translate a complex argument into a format that decision-makers can act on.
NHS commissioners need economic arguments that are honest, well-constructed, and mapped to their planning frameworks and population priorities. Pharmaceutical and medtech companies need to understand how those frameworks operate, where the system's pressure points are, and how to engage constructively with the people responsible for allocation decisions. The space between those two positions and the work of bridging it is where the most valuable partnerships are built.
CHASE’s teams combine deep NHS knowledge with life science industry expertise, supporting organisations on both sides to design programmes, build evidence, and navigate the commissioning landscape in a way that serves patients as much as it serves commercial objectives. If you are working through a market access challenge, a commissioning conversation, or the development of an NHS-industry partnership, get in touch with the CHASE team.
Explore our latest thinking, event updates and industry insights to stay informed.
The new VPAG rate of 14.5% takes effect on 1 April 2026. CHASE analyses what it means for pharmaceutical companies operating in the UK.
The NHS has the ambition, the data, & the investment but AI adoption is slow. CHASE explores how to close the gap between technology and patient benefit.
GP surgeries today often function as multi-million-pound organisations. To engage primary care, Pharma & medtech need to know how to talk to Practice Managers.
.svg)
